Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583344 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of GSK4532990 in Adults With NASH
A Phase 2 study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 284
- Enrollment target
- 20
- Study locations
NCT05583344 is a Phase 2 study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 284 participants, above the 184-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05583344, a Phase 2 study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 284 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK4532990
Study Locations (20)
California
- GSK Investigational Site - Huntington Park
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Orange
- GSK Investigational Site - Poway
- GSK Investigational Site - Rialto
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Santa Ana
- GSK Investigational Site - Van Nuys
Florida
- GSK Investigational Site - Bradenton
- GSK Investigational Site - Coral Gables
- GSK Investigational Site - Fort Myers
- GSK Investigational Site - Hallandale
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Chandler
- GSK Investigational Site - Mesa
Arkansas
- GSK Investigational Site - Jonesboro
- GSK Investigational Site - North Little Rock
Alabama
- GSK Investigational Site - Homewood
Colorado
- GSK Investigational Site - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2023-01-02 |
| Est. Completion | 2027-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05583344
The ClinicalTrials.gov registry entry for NCT05583344 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (54% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05583344 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05583344 about?
NCT05583344 is a clinical study titled "Phase 2b Study of GSK4532990 in Adults With NASH". The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be...
What is the current status of trial NCT05583344?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 284 participants. The study started on 2023-01-02. Estimated completion is 2027-04-05.
What conditions does trial NCT05583344 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT05583344?
The interventions under investigation include: Placebo (DRUG), GSK4532990 (DRUG).
Who is sponsoring clinical trial NCT05583344?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05583344 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Non-alcoholic Fatty Liver Disease
All registered trials for this condition
Nonalcoholic Fatty Liver Disease
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.